Market LIVE
Published markets; coverage varies by country
Product profile · United States

SOVUNA

 ·  Patent Litigation & Settlement History ↓

IngredientHYDROXYCHLOROQUINE SULFATE
Application typeNDA
Application214581
Product001
Dosage formTABLET
RouteORAL
Strength200MG
Approval date2022-01-14
Marketing statusPrescription
Status event—
ApplicantNOVITIUM PHARMA
Product source

Current GenericRadar decision

Year2022
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeAPPROVAL_YEAR_FALLBACK
Anchor date2022-01-14
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

No verified direct-reference Final ANDA or unrestricted TrueDS/DS-equivalent/full-coverage exclusivity anchor is established for this exact product. Apply the approval-year DR fallback under the review policy. Available hydroxychloroquine ANDAs belong to the PLAQUENIL reference family (NDA 009768). FDA letter 210441 identifies PLAQUENIL 200 mg, and 300 mg is an additional strength within that pre-existing application. No SOVUNA-specific Final ANDA is established.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-11 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
040081 / 001FINAL_APPROVAL · FINAL_APPROVED1994-09-30—TEVA PHARMACEUTICALS USANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040104 / 001FINAL_APPROVAL · FINAL_APPROVED1995-11-30—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040133 / 001FINAL_APPROVAL · FINAL_APPROVED1995-11-30—WATSON LABORATORIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040150 / 001FINAL_APPROVAL · FINAL_APPROVED1996-01-27—CREEKWOOD PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040274 / 001FINAL_APPROVAL · FINAL_APPROVED1998-05-29—AUROBINDO PHARMA USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040766 / 001FINAL_APPROVAL · FINAL_APPROVED2007-06-14—IPCA LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040760 / 001FINAL_APPROVAL · FINAL_APPROVED2007-08-15—HIKMA PHARMACEUTICALSNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
040657 / 001FINAL_APPROVAL · FINAL_APPROVED2007-09-21—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210441 / 001FINAL_APPROVAL · FINAL_APPROVED2018-05-01—APPCO PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
201691 / 001FINAL_APPROVAL · FINAL_APPROVED2018-05-08—ALKALOIDA CHEMICAL CO ZRTNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210577 / 001FINAL_APPROVAL · FINAL_APPROVED2018-05-15—AMNEAL PHARMACEUTICALS CO GMBHNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210543 / 001FINAL_APPROVAL · FINAL_APPROVED2018-07-06—CHARTWELL RX SCIENCES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210959 / 001FINAL_APPROVAL · FINAL_APPROVED2019-01-15—LAURUS LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213342 / 001FINAL_APPROVAL · FINAL_APPROVED2020-04-07—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212902 / 001FINAL_APPROVAL · FINAL_APPROVED2020-05-14—SENORES PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 15 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
040081 / 001TEVA PHARMACEUTICALS USAFINAL_APPROVAL · FINAL_APPROVED1994-09-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040104 / 001SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED1995-11-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040133 / 001WATSON LABORATORIES INCFINAL_APPROVAL · FINAL_APPROVED1995-11-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040150 / 001CREEKWOOD PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED1996-01-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040274 / 001AUROBINDO PHARMA USA INCFINAL_APPROVAL · FINAL_APPROVED1998-05-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040766 / 001IPCA LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2007-06-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040760 / 001HIKMA PHARMACEUTICALSFINAL_APPROVAL · FINAL_APPROVED2007-08-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
040657 / 001ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2007-09-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210441 / 001APPCO PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2018-05-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
201691 / 001ALKALOIDA CHEMICAL CO ZRTFINAL_APPROVAL · FINAL_APPROVED2018-05-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210577 / 001AMNEAL PHARMACEUTICALS CO GMBHFINAL_APPROVAL · FINAL_APPROVED2018-05-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210543 / 001CHARTWELL RX SCIENCES LLCFINAL_APPROVAL · FINAL_APPROVED2018-07-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210959 / 001LAURUS LABS LTDFINAL_APPROVAL · FINAL_APPROVED2019-01-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213342 / 001ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2020-04-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212902 / 001SENORES PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2020-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
REGULATORY_STATUS2022-01-14DECISION_BASISNo verified direct-reference Final ANDA or unrestricted TrueDS/DS-equivalent/full-coverage exclusivity anchor is established for this exact product. Apply the approval-year DR fallback under the review policy. Available hydroxychloroquine ANDAs belong to the PLAQUENIL reference family (NDA 009768). FDA letter 210441 identifies PLAQUENIL 200 mg, and 300 mg is an additional strength within that pre-existing application. No SOVUNA-specific Final ANDA is established.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.